What medications are recommended for gastroesophageal reflux disease (GERD)?

Medications for GERD

Start with a standard 4-8 week course of once-daily proton pump inhibitors (PPIs) for patients presenting with heartburn and regurgitation without alarm symptoms—this remains the first-line therapy with the strongest evidence for symptom relief and esophagitis healing. 1

First-Line Therapy: Proton Pump Inhibitors

• PPIs are the cornerstone of GERD treatment and should be offered as initial therapy for troublesome heartburn, regurgitation, and/or non-cardiac chest pain in patients without alarm symptoms 1
• The standard treatment duration is 4-8 weeks for uncomplicated GERD symptoms and 8 weeks for erosive esophagitis 2
• PPIs provide superior acid suppression compared to other medication classes and achieve the highest rates of esophagitis healing 3, 4
• Clinicians should emphasize the safety of PPIs when discussing treatment options with patients 1

Optimizing PPI Therapy

If symptoms persist on standard once-daily PPI:

• First optimize compliance and timing of the current PPI dose before escalating therapy 3
• Increase to twice-daily dosing only in specific circumstances: patients with Barrett's esophagus, laryngopharyngeal reflux disease, or incomplete response to once-daily dosing 2
• Consider switching to a different PPI formulation before dose escalation 1
• After adequate response, taper to the lowest effective dose to minimize long-term medication exposure 1

Add-On Therapies to PPIs

When PPI monotherapy is insufficient, consider these adjunctive medications:

H2-Receptor Antagonists (H2RAs)

• Add bedtime H2RAs for persistent nocturnal symptoms or objective evidence of nocturnal acid reflux on pH monitoring despite PPI treatment 2
• H2RAs provide additional nighttime acid suppression when breakthrough symptoms occur 4, 5

Prokinetic Agents

• Use as add-on therapy in patients with concomitant symptoms suggesting delayed gastric emptying (early satiety, bloating, nausea) 2
• Note that metoclopramide has not been proven definitively helpful for GERD symptom control and carries risk of side effects 5

Antacids and Alginates

• Antacids provide rapid but short-lived symptom relief and can be used for breakthrough symptoms 4, 5
• Alginate-containing formulations create a physical barrier and may be used as adjunctive therapy 2

Potassium-Competitive Acid Blockers (P-CABs)

P-CABs represent a newer class of acid suppressants with distinct advantages:

• Generally should NOT be used as first-line therapy for uninvestigated heartburn or nonerosive reflux disease due to cost, access barriers, and limited long-term safety data 1
• May be used in selected patients with documented acid-related reflux who fail twice-daily PPI therapy 1
• P-CABs should generally not be first-line for milder erosive esophagitis (Los Angeles grade A/B) 1
• P-CABs offer more rapid and potent acid inhibition than PPIs, with longer half-life (5-7 hours vs 1-2 hours) and acid-stable formulation 1
• Even modest clinical superiority over double-dose PPIs may not make P-CABs cost-effective as first-line therapy based on current U.S. pricing 1

Specialized Medications for Refractory GERD

Baclofen

• Inhibits transient lower esophageal sphincter relaxations, providing an option for persistent reflux symptoms 5
• Use is limited by central nervous system side effects 5

Neuromodulators

• Antidepressants are effective for treating visceral hypersensitivity in specific NERD subgroups and patients with functional overlap syndromes 2, 6
• Consider in patients with reflux hypersensitivity or functional heartburn diagnosed on pH-impedance monitoring 1

Common Pitfalls to Avoid

• Do not continue empiric PPI therapy indefinitely without objective confirmation of GERD—if therapy continues beyond 12 months in unproven GERD, perform endoscopy with prolonged wireless pH monitoring off PPI 1
• Do not perform empiric PPI trials for isolated extra-esophageal symptoms—these patients require upfront objective reflux testing off medication 1
• Do not use P-CABs as initial therapy when clinical superiority has not been demonstrated, as nonclinical factors make them less favorable first-line options 1
• Avoid assuming all persistent symptoms represent refractory GERD—many patients have functional disorders or non-acid reflux requiring different management approaches 1, 6

Medication Selection Algorithm

1. Start with once-daily PPI for 4-8 weeks in patients with typical symptoms and no alarm features 1
2. If inadequate response: optimize timing/compliance, then consider twice-daily PPI or switch PPI formulation 1, 2
3. If still inadequate: perform endoscopy and pH monitoring to confirm GERD phenotype 1
4. For confirmed refractory GERD on twice-daily PPI: consider P-CABs in selected cases 1
5. Add adjunctive therapy based on symptom pattern: H2RAs for nocturnal symptoms, prokinetics for delayed emptying symptoms, neuromodulators for hypersensitivity 2